April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Drs Cohen, Wu, and Ahn discuss HER2 in colorectal cancer, explaining that increased expression indicates possible benefit from HER2 inhibitors; Ahn summarized studies showing modest activity of dual HER2 inhibition compared to single agent trastuzumab.
The Role of Biomarker and Molecular Testing in CRC
Drs Wu, Ciombor, and Cohen discussed upfront molecular testing in patients with colorectal cancer to guide treatment, with Dr Ciombor reviewing HER2 testing methods and Dr Cohen noting liquid biopsy limitations.
Current Treatment Options for CRC
Drs Ahn and Cohen discuss the treatment of colorectal cancer, reviewing the available options and describing factors influencing treatment choice and use of maintenance therapy after initial response.
Overview of Colorectal Cancer (CRC)
Stacy A. Cohen, MD, provides an overview of colorectal cancer, noting increasing incidence in younger patients; Christina S. Wu, MB, BCh, MD, discussed possible reasons for more colorectal cancer in younger people, including genetic predisposition and exposures, though the causes remain unclear.
Avelumab Significantly Improves PFS Vs Chemo in dMMR/MSI-H Metastatic CRC
October 13th 2023Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.
The Future of BRAF-Mutant mCRC Management
October 13th 2023Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.
Approaches for Treatment Sequencing in Patients With HER2+ mCRC
September 29th 2023In a detailed conversation, Tanios Bekaii-Saab, MD, Daniel Ahn, DO, and Christina Wu, MB, BCh, MD, discuss various scenarios for treating HER2+ metastatic colorectal cancer, focusing on patient profiling, testing methods, and different sequencing strategies including the use of trastuzumab.
DESTINY-CRC02 Trial: Trastuzumab Deruxtecan for the Management of mCRC
September 22nd 2023Daniel Ahn, DO, and Tanios Bekaii-Saab, MD, detail the findings of the DESTINY-CRC02 trial, which examined the efficacy of trastuzumab deruxtecan at different dosing levels in breast cancer and gastric cancer patients.